MedTrace Logo

Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CAD

NCT03693560 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2023-06-13

No results posted yet for this study

Summary

The aim of this study is to evaluate the effect of adding Vildagliptin versus Glimepiride to Metformin on markers of inflammation, thrombosis, and atherosclerosis in diabetic patients with symptomatic Coronary artery diseases.

The pre-specified established biological markers of inflammation, thrombosis, and atherosclerosis will include: Interleukin 1 beta (IL-1 beta)), hs-CRP, Atherogenic index and coronary risk index, Lipid profile. and adiponectin levels..

Conditions

Interventions

DRUG

Vildagliptin 50 mg Oral Tablet

Patients who the endocrinologist prescribed them Vildagliptin 50 mg Oral Tablet plus their Metformin 1000 mg Oral Tablet to control their blood sugar level.

DRUG

Metformin 1000 mg Oral Tablet

Patients with Coronary artery diseases.and uncontrolled Diabetes Mellitus type 2 who's taking Metformin 1000 mg Oral Tablet only will be enrolled from endocrinology clinic.

DRUG

Glimepiride upto 4 mg Oral Tablet

Patients who the endocrinologist prescribed them Glimepiride 4 mg oral tablet plus their Metformin 1000 mg Oral Tablet

Sponsors & Collaborators

  • Tanta University

    collaborator OTHER

  • Damanhour University

    lead OTHER

Principal Investigators

  • Gamal Omran, PhD · Faculty of Pharmacy - Damanhour University.

  • Tarek Mostafa, PhD · Tanta University

  • Ahmed skokry, PhD · Alex.Armed Forces Hospital.

  • Rehab Werida, PhD · Faculty of Pharmacy - Damanhour University.

  • Mahmoud kabel · Faculty of Pharmacy - Damanhour University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-08
Primary Completion
2019-09-10
Completion
2019-10-10

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03693560 on ClinicalTrials.gov